Two Anti-Anxiety Drugs: A Psychoneuroendocrine Study

24Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Eight males were studied during 27 weeks, including two periods of five weeks during which they received clinical doses of sodium amylobarbitone and benzoctamine. Substitution of placebo for either drug caused raised anxiety and impairment of mental concentration. The drugs reduced restlessness during sleep and reduced paradoxical sleep. By the fifth week of sodium amylobarbitone, although sleep was still less restless in the early night it was more restless than normal in the late night Blood samples were taken half-hourly during sleep by indwelling venous catheter. Plasma growth hormone concentration was little affected during drug administration but rose temporarily after withdrawal. There was a reduction of plasma corticosteroid concentration during sleep throughout administration of the drugs and a rebound above normal during the first withdrawal week. © 1973, British Medical Journal Publishing Group. All rights reserved.

Cite

CITATION STYLE

APA

Ogunremi, O. O., Adamson, L., Březinová, V., Maclean, A. W., Oswald, I., Percy-Robb, I. W., & Hunter, W. M. (1973). Two Anti-Anxiety Drugs: A Psychoneuroendocrine Study. British Medical Journal, 2(5860), 202–205. https://doi.org/10.1136/bmj.2.5860.202

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free